Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Len + pembro metastatic clear cell renal cell carcinoma

Chung Han-Lee • 29 May 2020
ASCO 2020
Genitourinary Cancer Kidney Cancer Lenvatinib Pembrolizumab

Chung Han-Lee, MD, PhD, Memorial Sloan Kettering Cancer Center, New York City, NY, USA, gives an overview of data coming from the phase II trial (NCT02501096) of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Chung Han-Lee

1:15
Q-TWiST of lenvatinib + everolimus in advanced RCC
Chung Han-Lee • 29 May 2020

Related Videos

10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
3:07
Serum thymidine kinase 1 as a predicative biomarker in prostate cancer
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals